Fore Pharmas latest report ‘Global Urinary Incontinence Drug Pipeline Capsule – 2011 is an outline of all the key research and development (R&D) activities of the global urinary incontinence drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the urinary incontinence drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Urinary Incontinence: Overview
- Urinary Incontinence Drug Pipeline Overview
- Urinary Incontinence Phase 3 Clinical Trial Drug Pipeline Insights
- Urinary Incontinence Phase 2 Clinical Trial Drug Pipeline Insights
- Urinary Incontinence Phase 1 Clinical Trial Drug Pipeline Insights
- Urinary Incontinence Preclinical Research Drug Pipeline Insights
- Urinary Incontinence Drug Discovery Pipeline Insights
- Geographic Landscape of Urinary Incontinence R&D Activities
- Urinary Incontinence R&D Activities in North America
- Urinary Incontinence R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Urinary Incontinence Drug Market

1. Urinary Incontinence: Disease Definition
2. Urinary Incontinence Drug Pipeline Overview
3. Urinary Incontinence Phase 3 Clinical Trial Drug Pipeline Insights
4. Urinary Incontinence Phase 2 Clinical Trial Drug Pipeline Insights
5. Urinary Incontinence Phase 1 Clinical Trial Drug Pipeline Insights
6. Urinary Incontinence Preclinical Research Drug Pipeline Insights
7. Urinary Incontinence Drug Discovery Pipeline Insights
8. Geographic Landscape of Urinary Incontinence R&D Activities
8.1 Urinary Incontinence R&D Activities in North America
8.2 Urinary Incontinence R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Urinary Incontinence Drug Market
10 Research Methodology Table 1: Urinary Incontinence Drug Pipeline: Phase 3 Clinical Trial

Table 2: Urinary Incontinence Drug Pipeline: Phase 2 Clinical Trial
Table 3: Urinary Incontinence Drug Pipeline: Phase 1 Molecules
Table 4: Urinary Incontinence Drug Pipeline: Preclinical Research
Table 5: Urinary Incontinence R&D Activities by Geography
Table 6: Urinary Incontinence Drug Pipeline: North America
Table 7: Urinary Incontinence Drug Pipeline: Europe
Table 8: Urinary Incontinence Drug Pipeline: Licensing Activities

 Figure 1 : Urinary Incontinence Drug Pipeline Molecules by Stages
Figure 2 : Urinary Incontinence R&D Activities by Geography